ClinicalTrials.gg
CompletedNCT01751113SCO116572Updated Mar 8, 2017Results posted

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects

A Phase 4 interventional study of fluticasone propionate/salmeterol and tiotropium bromide in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 3 sites in Japan. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
36th of 59
53 · median 95
Started
2013
with 3 others
Phase 4
28 of 59
2 open now
Registered
31st of 59
by date
Lead sponsor
25 of 59
GlaxoSmithKline

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 36th largest by enrollment, is one of 4 that started in 2013, is one of 28 in phase 4, and was the 31st registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects on lung function of a combination of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg once daily alone and ADOAIR 50/250mcg twice daily alone) in Japanese subjects with COPD. The study will utilize a three-way cross-over design with a 2-week wash-out period between each 4-week consecutive treatment period. The aim is to support the rationale for "triple combination" therapy by demonstrating that treatment with both ADOAIR and tiotropium can potentially produce improved, clinically relevant effects compared with either treatment alone.

This study will utilize a range of lung function measures in order to fully assess the benefits of triple therapy. The primary endpoint will be based on airways conductance measured using plethysmography (sGaw measured over 4hours post dose (AUC 0-4hr) on Day 28). Secondary endpoints will include lung function measures based on plethysmography and spirometry. The lung function measures will be supported by measurement of the use of relief salbutamol .

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 40 - 80 years inclusive
  • Has an established clinical history of (defined as per the GOLD definition)
  • A signed and dated written is obtained from the subject prior to study participation
  • The subject has a post-bronchodilator of >=30% to =\<75% of predicted normal at Visit 1
  • The subject has a post-bronchodilator FEV1/ FVC ratio \<70% at Visit 1
  • The subject achieves a score of 1 on the Modified Medical Research Council (mMRC) Dyspnoea Scale at Visit 1
  • The subject is a current or ex-smoker with a smoking history of > 10 pack-years (10 pack years is defined as 20 cigarettes per day for 10 years, or 10 cigarettes (or equivalent if subject smoked cigars or a pipe) per day for 20 years). Ex-smokers are required to have stopped smoking for at least 6 months prior to visit 1. Ex-smokers who stopped smoking less than 6 months ago will be defined as current smokers.
  • \<450 msec at Visit 1; or for patients with Bundle Branch Block QTc should be \<480 msec.

(QTc(F) \<450msec, or \<480 in subjects with right bundle branch block, should be confirmed by the mean of three readings or one reading)

  • \< 2xULN and /ALP \< 1.5xULN (>35% direct bilirubin)
  • A female is eligible to enter this study if she is: i)of non- (i.e. physiologically incapable of becoming pregnant, including any female who is ), ii)of child-bearing potential, but has a negative urinary pregnancy test at screening and agrees to take precautions (including abstinence) which are adequate to prevent pregnancy during the study or iii)not a nursing mother

Exclusion criteria

Exclusion Criteria:

  • Has had a exacerbation within the 4 weeks prior to Visit 1
  • Had any changes in COPD medication in the 4 weeks prior to Visit 1
  • Has plan to change the dosage of Xanthines or to stop receiving it during the study
  • Has a current medical diagnosis of asthma
  • Has a medical diagnosis of narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction that in the opinion of the investigator should prevent them from entering the study Note: As with other anticholinergic drugs, subjects with narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction should only be entered into the study at the Investigator's discretion
  • Has known respiratory disorders other than COPD (e.g. lung cancer, sarcoidosis, tuberculosis or lung fibrosis)
  • Has undergone lung surgery e.g., lung transplant and/or lung volume reduction
  • Is currently receiving pulmonary rehabilitation
  • Had a chest X-ray indicating diagnosis other than COPD that might interfere with the study (chest X-ray to be taken at entry, if subject has not had one or CT image taken within 3 months of Visit 1)
  • Requires regular (daily) or long term oxygen therapy (LTOT). (LTOT is defined as . 12 hours oxygen use per day)
  • Requires regular treatment with oral, parenteral, or depot or has received 2 or more periods of oral corticosteroids for COPD exacerbation in the last 6 months
  • Received oral, parenteral, or depot corticosteroids in the 4 weeks prior to Visit 1
  • Received antibiotic therapy for either a lower respiratory tract infection or for COPD exacerbation within the 4 weeks prior to Visit 1
  • Has been hospitalized for a COPD exacerbation in the last year
  • Receiving non-selective β-blockers (except eye drops)
  • Has serious, uncontrolled disease likely to interfere with the study (e.g. Left Ventricular failure, anaemia, renal or hepatic disease or serious psychological disorders)
  • Received any other drugs within 4 weeks (or 5 half lives) prior to Visit 1
  • Has, in the opinion of the investigator, evidence of alcohol, drug or solvent abuse
  • Has a known or suspected to β2-agonists, inhaled steroids, anticholinergic treatments or any components of the formulations (e.g. lactose or milk protein)
  • Has previously been enrolled and randomized to this study
  • Are not considered able to tolerate three 2-weeks according to the study schedule with all COPD medications removed apart from rescue use of SALBUTAMOL via MDI (inhaled PRN use).
  • Is not eligible to participate this study in the opinion of the investigator/subinvestigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    fluticasone propionate/salmeterol

    250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)

    Drug: fluticasone propionate/salmeterol

  • Active comparator
    tiotropium bromide

    18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)

    Drug: tiotropium bromide

  • Active comparator
    fluticasone propionate/salmeterol plus tiotropium bromide

    250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)

    Drug: fluticasone propionate/salmeterol plus tiotropium bromide

Interventions

  • Drugfluticasone propionate/salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)

    Also known as: ADOAIR is a registered trade mark of the GlaxoSmithKlline group of companies.

  • 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)

  • Drugfluticasone propionate/salmeterol plus tiotropium bromide

    Drug pages: Fluticasone · Salmeterol Xinafoate · Tiotropium

    250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)

    Also known as: ADOAIR is a registered trade mark of the GlaxoSmithKlline group of companies.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period

    sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sGaw. The AUC was determined by using the trapezoidal rule and then dividing by the relevant time interval. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, period and Baseline sGaw fitted as fixed effects and participants fitted as a random effect. Treatment ratios of all statistical comparisons were calculated by taking the anti-log of the difference between the Least Square (LS) means.

    Time frame: Day 28 of each treatment period (up to 35 days)

Secondary outcomes

  1. AUC (0-4hr) Specific Airway Resistance (sRaw) After the Morning Dose of Each Study Medication at Day 28 of Each Treatment Period

    sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sRaw. The AUC was determined by using the trapezoidal rule and then dividing by the relevant time interval. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, period and Baseline sRaw fitted as fixed effects and participants fitted as a random effect. Treatment ratios of all statistical comparisons were calculated by taking the anti-log of the difference between the LS means.

    Time frame: Day 28 of each treatment period (up to 35 days)

  2. Post-dose sGaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period

    sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sGaws. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, time, period, a treatment by time interaction and Baseline sGaw fitted as fixed effects and participant fitted as a random effect.

    Time frame: Day 28 of each treatment period (up to 35 days)

  3. Post-dose sRaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period

    sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sRaw. A natural logarithmic transformation was applied and the data was analysed by a mixed model including treatment, time, period, a treatment by time interaction and Baseline sRaw fitted as fixed effects and participant fitted as a random effect.

    Time frame: Day 28 of each treatment period (up to 35 days)

  4. Trough Forced Expiratory Volume in One Second (FEV1), Forced Vital Capacity (FVC), Inspiratory Capacity (IC), RV, TLC, and TGV at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. IC is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Total lung capacity (TLC) is the maximum volume to which the lungs can be expanded with the greatest possible inspiratory effort; it is equal to the vital capacity (VC) plus the residual volume (RV). RV is defined as the volume of air remaining in the lungs. after a maximal exhalation. Thoracic gas volume at functional residual capacity (TGV) is defined as the volume of intrathoracic gas at the time the airway is occluded for the plethysmographic measurement at the end of a normal expiration. Trough values were the values taken pre-dose.

    Time frame: Day 28 of each treatment period (up to 35 days)

  5. Trough FEV1/FVC Ratio, at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. Trough values were the values taken pre-dose.

    Time frame: Day 28 of each treatment period (up to 35 days)

  6. Trough sRaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

    sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Trough values were the values taken pre-dose.

    Time frame: Day 28 of each treatment period (up to 35 days)

  7. Trough sGaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

    sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Trough values were the values taken pre-dose.

    Time frame: Day 28 of each treatment period (up to 35 days)

  8. Post-dose FEV1, FVC, IC, RV, TLC and TGV (Measured at Trough) at Day 28 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. IC is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Total lung capacity (TLC) is the maximum volume to which the lungs can be expanded with the greatest possible inspiratory effort; it is equal to the vital capacity (VC) plus the RV. RV is defined as the volume of air remaining in the lungs after a maximal exhalation. Thoracic gas volume at functional residual capacity (TGV) is defined as the volume of intrathoracic gas at the time the airway is occluded for the plethysmographic measurement at the end of a normal expiration.

    Time frame: Day 28 of each treatment period (up to 35 days)

  9. Post-dose FEV1/FVC Ratio (Measured at Trough) at Day 28 of Each Treatment Period

    FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements.

    Time frame: Day 28 of each treatment period (up to 35 days)

  10. Use of Rescue Medication (Number of Occasions Per 24-hour Period) as Recorded in the Daily Record Card at Day 28 of Each Treatment Period

    Participants were given daily record cards for daily completion during the run-in, washout and treatment periods. Each morning, participants recorded the number of occasions in the last 24 hours when they had used their rescue medication (salbutamol) for symptomatic relief of COPD symptoms.

    Time frame: Day 28 of each treatment period (up to 35 days)

07

Results

Posted Sep 8, 2014

Participant flow

A total of 53 Japanese participants with moderate or severe chronic obstructive pulmonary disease (COPD) entered the run-in period.

Treatment Period 1 (4 Weeks)
Participant flow — Treatment Period 1 (4 Weeks)
MilestoneSequence 1: Ado 50/250 µg+Tio 18 µg, Tio 18 µg, Ado 50/250 µgSequence 2: Tio 18 µg, Ado 50/250 µg, Ado 50/250 µg+Tio 18 µgSequence 3: Ado 50/250 µg, Ado 50/250 µg+Tio 18 µg, Tio 18 µgSequence 4: Ado 50/250 µg, Tio 18 µg, Ado 50/250 µg+Tio 18 µgSequence 5: Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µgSequence 6: Tio 18 µg, Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg
Started8899910
Completed8898810
Not completed000110
Withdrew: Adverse event000110
Washout Period 1 (2 Weeks)
Participant flow — Washout Period 1 (2 Weeks)
MilestoneSequence 1: Ado 50/250 µg+Tio 18 µg, Tio 18 µg, Ado 50/250 µgSequence 2: Tio 18 µg, Ado 50/250 µg, Ado 50/250 µg+Tio 18 µgSequence 3: Ado 50/250 µg, Ado 50/250 µg+Tio 18 µg, Tio 18 µgSequence 4: Ado 50/250 µg, Tio 18 µg, Ado 50/250 µg+Tio 18 µgSequence 5: Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µgSequence 6: Tio 18 µg, Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg
Started8898810
Completed8898810
Not completed000000
Treatment Period 2 (4 Weeks)
Participant flow — Treatment Period 2 (4 Weeks)
MilestoneSequence 1: Ado 50/250 µg+Tio 18 µg, Tio 18 µg, Ado 50/250 µgSequence 2: Tio 18 µg, Ado 50/250 µg, Ado 50/250 µg+Tio 18 µgSequence 3: Ado 50/250 µg, Ado 50/250 µg+Tio 18 µg, Tio 18 µgSequence 4: Ado 50/250 µg, Tio 18 µg, Ado 50/250 µg+Tio 18 µgSequence 5: Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µgSequence 6: Tio 18 µg, Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg
Started8898810
Completed8898810
Not completed000000
Washout Period 2 (2 Weeks)
Participant flow — Washout Period 2 (2 Weeks)
MilestoneSequence 1: Ado 50/250 µg+Tio 18 µg, Tio 18 µg, Ado 50/250 µgSequence 2: Tio 18 µg, Ado 50/250 µg, Ado 50/250 µg+Tio 18 µgSequence 3: Ado 50/250 µg, Ado 50/250 µg+Tio 18 µg, Tio 18 µgSequence 4: Ado 50/250 µg, Tio 18 µg, Ado 50/250 µg+Tio 18 µgSequence 5: Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µgSequence 6: Tio 18 µg, Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg
Started8898810
Completed8898810
Not completed000000
Treatment Period 3 (4 Weeks)
Participant flow — Treatment Period 3 (4 Weeks)
MilestoneSequence 1: Ado 50/250 µg+Tio 18 µg, Tio 18 µg, Ado 50/250 µgSequence 2: Tio 18 µg, Ado 50/250 µg, Ado 50/250 µg+Tio 18 µgSequence 3: Ado 50/250 µg, Ado 50/250 µg+Tio 18 µg, Tio 18 µgSequence 4: Ado 50/250 µg, Tio 18 µg, Ado 50/250 µg+Tio 18 µgSequence 5: Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µgSequence 6: Tio 18 µg, Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg
Started8898810
Completed889889
Not completed000001
Withdrew: Adverse event000001

Outcome measures

PrimaryArea Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period

sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sGaw. The AUC was determined by using the trapezoidal rule and then dividing by the relevant time interval. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, period and Baseline sGaw fitted as fixed effects and participants fitted as a random effect. Treatment ratios of all statistical comparisons were calculated by taking the anti-log of the difference between the Least Square (LS) means.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · 1/kilopascal*second (1/kPa*s)
Area Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period
1/kilopascal*second (1/kPa*s)Ado 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Area Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period0.854 ± 0.01830.737 ± 0.01830.663 ± 0.0182
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Auc ratio: 1.158 · 95% CI 1.100 to 1.219
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Auc ratio: 1.288 · 95% CI 1.224 to 1.355
SecondaryAUC (0-4hr) Specific Airway Resistance (sRaw) After the Morning Dose of Each Study Medication at Day 28 of Each Treatment Period

sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sRaw. The AUC was determined by using the trapezoidal rule and then dividing by the relevant time interval. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, period and Baseline sRaw fitted as fixed effects and participants fitted as a random effect. Treatment ratios of all statistical comparisons were calculated by taking the anti-log of the difference between the LS means.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · kPa*s
AUC (0-4hr) Specific Airway Resistance (sRaw) After the Morning Dose of Each Study Medication at Day 28 of Each Treatment Period
kPa*sAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
AUC (0-4hr) Specific Airway Resistance (sRaw) After the Morning Dose of Each Study Medication at Day 28 of Each Treatment Period1.181 ± 0.01881.380 ± 0.01891.525 ± 0.0188
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Auc ratio: 0.856 · 95% CI 0.812 to 0.902
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Auc ratio: 0.774 · 95% CI 0.735 to 0.816
SecondaryPost-dose sGaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period

sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sGaws. A natural logarithmic transformation was applied and the data was analyzed by a mixed model including treatment, time, period, a treatment by time interaction and Baseline sGaw fitted as fixed effects and participant fitted as a random effect.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · 1/kPa*s
Post-dose sGaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period
1/kPa*sAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
30 min0.833 ± 0.02410.705 ± 0.02410.639 ± 0.0240
75 min0.873 ± 0.02410.743 ± 0.02410.652 ± 0.0240
120 min0.885 ± 0.02410.769 ± 0.02410.680 ± 0.0240
240 min0.855 ± 0.02410.750 ± 0.02410.690 ± 0.0240
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.181 · 95% CI 1.104 to 1.263Statistical data for 30 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.303 · 95% CI 1.219 to 1.393Statistical data for 30 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.175 · 95% CI 1.099 to 1.257Statistical data for 75 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.340 · 95% CI 1.253 to 1.432Statistical data for 75 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.151 · 95% CI 1.076 to 1.231Statistical data for 120 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.301 · 95% CI 1.217 to 1.391Statistical data for 120 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.141 · 95% CI 1.067 to 1.220Statistical data for 240 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.239 · 95% CI 1.159 to 1.325Statistical data for 240 minutes
SecondaryPost-dose sRaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period

sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Plethysmography was performed to assess sRaw. A natural logarithmic transformation was applied and the data was analysed by a mixed model including treatment, time, period, a treatment by time interaction and Baseline sRaw fitted as fixed effects and participant fitted as a random effect.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · kPa*s
Post-dose sRaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period
kPa*sAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
30 min1.201 ± 0.02401.419 ± 0.02401.567 ± 0.0240
75 min1.146 ± 0.02401.348 ± 0.02401.535 ± 0.0240
120 min1.129 ± 0.02401.300 ± 0.02401.468 ± 0.0240
240 min1.170 ± 0.02401.334 ± 0.02401.446 ± 0.0240
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.846 · 95% CI 0.792 to 0.905Statistical data for 30 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.767 · 95% CI 0.717 to 0.819Statistical data for 30 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.850 · 95% CI 0.795 to 0.909Statistical data for 75 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.746 · 95% CI 0.698 to 0.798Statistical data for 75 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.868 · 95% CI 0.812 to 0.928Statistical data for 120 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.769 · 95% CI 0.719 to 0.822Statistical data for 120 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.877 · 95% CI 0.820 to 0.938Statistical data for 240 minutes
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.809 · 95% CI 0.757 to 0.865Statistical data for 240 minutes
SecondaryTrough Forced Expiratory Volume in One Second (FEV1), Forced Vital Capacity (FVC), Inspiratory Capacity (IC), RV, TLC, and TGV at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. IC is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Total lung capacity (TLC) is the maximum volume to which the lungs can be expanded with the greatest possible inspiratory effort; it is equal to the vital capacity (VC) plus the residual volume (RV). RV is defined as the volume of air remaining in the lungs. after a maximal exhalation. Thoracic gas volume at functional residual capacity (TGV) is defined as the volume of intrathoracic gas at the time the airway is occluded for the plethysmographic measurement at the end of a normal expiration. Trough values were the values taken pre-dose.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Least squares mean · Liters (L)
Trough Forced Expiratory Volume in One Second (FEV1), Forced Vital Capacity (FVC), Inspiratory Capacity (IC), RV, TLC, and TGV at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
Liters (L)Ado 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
FEV11.823 ± 0.01471.666 ± 0.01471.706 ± 0.0147
FVC3.575 ± 0.01823.493 ± 0.01823.439 ± 0.0182
IC2.460 ± 0.01772.406 ± 0.01792.395 ± 0.0174
RV3.021 ± 0.02823.129 ± 0.02863.123 ± 0.0278
TLC6.511 ± 0.01896.524 ± 0.01916.525 ± 0.0186
TGV4.053 ± 0.02064.118 ± 0.02104.129 ± 0.0204
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Mean difference of fev1: 0.157 · 95% CI 0.116 to 0.198Statistical data for FEV1
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference of fev1: 0.118 · 95% CI 0.077 to 0.159Statistical data for FEV1
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.002 · Mean difference of fvc: 0.082 · 95% CI 0.031 to 0.133Statistical data for FVC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference of fvc: 0.135 · 95% CI 0.084 to 0.186Statistical data for FVC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.035 · Mean difference of ic: 0.054 · 95% CI 0.004 to 0.104Statistical data for IC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.011 · Mean difference of ic: 0.064 · 95% CI 0.015 to 0.114Statistical data for IC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.009 · Mean difference of rv: -0.107 · 95% CI -0.187 to -0.028Statistical data for RV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.012 · Mean difference of rv: -0.102 · 95% CI -0.180 to -0.023Statistical data for RV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.632 · Mean difference of tlc: -0.013 · 95% CI -0.066 to 0.040Statistical data for TLC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.596 · Mean difference of tlc: -0.014 · 95% CI -0.067 to 0.038Statistical data for TLC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.028 · Mean difference of tgv: -0.065 · 95% CI -0.123 to -0.007Statistical data for TGV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.010 · Mean difference of tgv: -0.075 · 95% CI -0.133 to -0.018Statistical data for TGV
SecondaryTrough FEV1/FVC Ratio, at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. Trough values were the values taken pre-dose.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Least squares mean · Ratio of FEV1/FVC
Trough FEV1/FVC Ratio, at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
Ratio of FEV1/FVCAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Trough FEV1/FVC Ratio, at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period0.513 ± 0.00320.481 ± 0.00320.496 ± 0.0032
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Fev1/fvc ratio: 0.032 · 95% CI 0.023 to 0.041Statistical data for FEV1/FVC ratio
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Fev1/fvc ratio: 0.017 · 95% CI 0.008 to 0.026Statistical data for FEV1/FVC ratio
SecondaryTrough sRaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

sRaw is a measure of airways resistance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Trough values were the values taken pre-dose.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · kPa*s
Trough sRaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
kPa*sAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Trough sRaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period1.391 ± 0.02881.666 ± 0.02861.732 ± 0.0284
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.835 · 95% CI 0.770 to 0.905
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 0.803 · 95% CI 0.741 to 0.869
SecondaryTrough sGaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period

sGaw is a measure of airways conductance and is intimately related to the diameter of the airways and consequently the level of bronchodilation. Trough values were the values taken pre-dose.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Geometric mean · 1/kPa*s
Trough sGaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
1/kPa*sAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Trough sGaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period0.720 ± 0.02870.600 ± 0.02850.577 ± 0.0284
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.200 · 95% CI 1.108 to 1.301
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = <0.001 · Specific airway conductance ratio: 1.249 · 95% CI 1.153 to 1.352
SecondaryPost-dose FEV1, FVC, IC, RV, TLC and TGV (Measured at Trough) at Day 28 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements. IC is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Total lung capacity (TLC) is the maximum volume to which the lungs can be expanded with the greatest possible inspiratory effort; it is equal to the vital capacity (VC) plus the RV. RV is defined as the volume of air remaining in the lungs after a maximal exhalation. Thoracic gas volume at functional residual capacity (TGV) is defined as the volume of intrathoracic gas at the time the airway is occluded for the plethysmographic measurement at the end of a normal expiration.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Least squares mean · Liters (L)
Post-dose FEV1, FVC, IC, RV, TLC and TGV (Measured at Trough) at Day 28 of Each Treatment Period
Liters (L)Ado 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
FEV11.766 ± 0.02691.605 ± 0.02691.664 ± 0.0269
FVC3.535 ± 0.04033.430 ± 0.04033.387 ± 0.0403
IC2.344 ± 0.04152.351 ± 0.04142.351 ± 0.0405
RV3.045 ± 0.05433.275 ± 0.05423.234 ± 0.0533
TLC6.487 ± 0.03956.588 ± 0.03946.592 ± 0.0386
TGV4.147 ± 0.04144.239 ± 0.04144.238 ± 0.0405
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Mean difference of fev1: 0.161 · 95% CI 0.086 to 0.236Statistical data for FEV1
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.008 · Mean difference of fev1: 0.103 · 95% CI 0.028 to 0.178Statistical data for FEV1
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.051 · Mean difference of fvc: 0.104 · 95% CI 0.000 to 0.209Statistical data for FVC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.006 · Mean difference of fvc: 0.148 · 95% CI 0.043 to 0.253Statistical data for FVC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.890 · Mean difference of ic: -0.008 · 95% CI -0.120 to 0.104Statistical data for IC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.890 · Mean difference of ic: -0.008 · 95% CI -0.118 to 0.103Statistical data for IC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = <0.001 · Mean difference of rv: -0.229 · 95% CI -0.355 to -0.103Statistical data for RV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.003 · Mean difference of rv: -0.189 · 95% CI -0.314 to -0.064Statistical data for RV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.055 · Mean difference of tlc: -0.101 · 95% CI -0.204 to 0.002Statistical data for TLC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.044 · Mean difference of tlc: -0.105 · 95% CI -0.206 to -0.003Statistical data for TLC
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg QD · Mixed Models Analysis · p = 0.085 · Mean difference of tgv: -0.092 · 95% CI -0.197 to 0.013Statistical data for TGV
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.083 · Mean difference of tgv: -0.091 · 95% CI -0.195 to 0.012Statistical data for TGV
SecondaryPost-dose FEV1/FVC Ratio (Measured at Trough) at Day 28 of Each Treatment Period

FEV1 is a measure of lung function and the maximal amount of air that can be forcefully exhaled in one second. FVC is defined as the amount of air that can forcibly be blown out after a full inspiration. FEV1 and FVC data was obtained by spirometry measurements.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Least squares mean · Ratio of FEV1/FVC
Post-dose FEV1/FVC Ratio (Measured at Trough) at Day 28 of Each Treatment Period
Ratio of FEV1/FVCAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg BIDAdo 50/250 µg BID
Post-dose FEV1/FVC Ratio (Measured at Trough) at Day 28 of Each Treatment Period0.500 ± 0.00520.472 ± 0.00520.492 ± 0.0052
Statistical analysis
  • Ado 50/250 µg BID+Tio 18 µg QD vs Tio 18 µg BID · Mixed Models Analysis · p = <0.001 · Fev1/fvc ratio: 0.027 · 95% CI 0.014 to 0.041Statistical data for FEV1/FVC ratio
  • Ado 50/250 µg BID+Tio 18 µg QD vs Ado 50/250 µg BID · Mixed Models Analysis · p = 0.223 · Fev1/fvc ratio: 0.008 · 95% CI -0.005 to 0.021Statistical data for FEV1/FVC ratio
SecondaryUse of Rescue Medication (Number of Occasions Per 24-hour Period) as Recorded in the Daily Record Card at Day 28 of Each Treatment Period

Participants were given daily record cards for daily completion during the run-in, washout and treatment periods. Each morning, participants recorded the number of occasions in the last 24 hours when they had used their rescue medication (salbutamol) for symptomatic relief of COPD symptoms.

Time frame:
Day 28 of each treatment period (up to 35 days)
Reported as:
Mean · Number of occasions
Use of Rescue Medication (Number of Occasions Per 24-hour Period) as Recorded in the Daily Record Card at Day 28 of Each Treatment Period
Number of occasionsAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Treatment, n=20, 18, 170.2 ± 0.620.3 ± 0.820.2 ± 0.55
Washout, n=15, 15, 110.4 ± 0.810.5 ± 1.240.4 ± 1.01

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of administration of the study drug until follow-up contact (up to Week 18).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ado 50/250 µg BID+Tio 18 µg QD—2/52 (3.8%)15/52 (28.8%)
Tio 18 µg QD—0/51 (0%)8/51 (15.7%)
Ado 50/250 µg BID—0/51 (0%)11/51 (21.6%)
Most frequent serious events
Most frequent serious events
EventAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
Prinzmetal anginaCardiac disorders1/520/510/51
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders1/520/510/51
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAdo 50/250 µg BID+Tio 18 µg QDTio 18 µg QDAdo 50/250 µg BID
DysphoniaRespiratory, thoracic and mediastinal disorders5/521/513/51
NasopharyngitisInfections and infestations3/521/511/51
ArthralgiaMusculoskeletal and connective tissue disorders2/520/510/51
HeadacheNervous system disorders0/521/510/51
HypertensionVascular disorders0/521/510/51
Productive coughRespiratory, thoracic and mediastinal disorders0/521/510/51
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/520/511/51
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders0/520/511/51
ConstipationGastrointestinal disorders0/520/511/51
Dry mouthGastrointestinal disorders1/521/511/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µg
Mean67.2 ± 6.56
Sex: Female, Male
Sex: Female, Male(Participants)Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µg
Female1
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ado 50/250 µg+Tio 18 µg, Ado 50/250 µg, Tio 18 µg
Asian - Japanese Heritage53
08

Study locations

3 sites
  • GSK Investigational Site
    Hokkaido, 070-8644, Japan
  • GSK Investigational Site
    Ibaraki, 319-1113, Japan
  • GSK Investigational Site
    Osaka, 530-0001, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Dec 17, 2012
Start
Feb 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Sep 8, 2014
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01751113
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 17, 2012
Start date
Feb 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Sep 8, 2014
Last update
Mar 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate · Tiotropium

Start the discussion